Seventeen in '17. It might sound like a slogan, but it's actually a reference to the size of the global HIV drug market. In 2017, the HIV market topped $17 billion, according to data from market research firm IMARC Group. The best-selling HIV drugs last year were Genvoya, Triumeq, Truvada, Tivicay, and Atripla.